Efforts of the WHO/IUATLD to solve the problem of poor bioavailability of rifampicin from FDC anti-tuberculosis products: is a change required in the direction of the approach in view of recent findings?
Singh
S
S
D000995:Antitubercular Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001682:Biological Availability; D004338:Drug Combinations; D006801:Humans; D012293:Rifampin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*; D014944:World Health Organization
D000995:Antitubercular Agents; D004338:Drug Combinations; D012293:Rifampin